Instructions for Guttalax (sodium picosulfate)
English Product Name Guttalax
Guttalax®
Release Form
tab. 5 mg: 20 or 50 pcs.
drops d/ingestion 0.75 g/100 ml: fl. 30 ml with drip plug
drops d/ingestion 0.75 g/100 ml: fl. 15 ml with drip plug
Description Guttalax
Administered as a clear, colorless to yellowish or slightly yellowish-brown, slightly viscous solution.
100 ml
sodium picosulfate monohydrate 0.75 g
Auxiliary substances: sodium benzoate - 0.2 g, sodium citrate dihydrate - 0.15 g, sorbitol liquid (non-crystallizing) - 64.37 g, citric acid monohydrate - 0.14 g, purified water - 49.89 g.
30 ml - plastic bottles (1) with a plug-dropper - cardboard packs.
Tablets are white, round, flat-cylindrical, with beveled edges, on one side of the tablet engraved "5L" on both sides of the risk separation, almost odorless.
ATX codes
A06AB08 Sodium picosulfate
Clinical and pharmacological groups / Group affiliation
Laxative
Active ingredient
sodium picosulfate monohydrate
Pharmacotherapeutic group Guttalax
Laxative
Retention conditions Guttalax
The drug should be stored in a place inaccessible to children at a temperature not exceeding 30 °C, not frozen.
Expiration date
Shelf life is 3 years. Do not apply after expiration of the shelf life indicated on the package.
Pharmacological effect Guttalax
Sodium picosulfate is an active substance that belongs to the group of laxatives triarylmethane. As a local laxative, sodium picosulfate stimulates the lining of the large intestine after bacterial cleavage in it. This leads to increased peristalsis and retention of water and electrolytes in the large intestine. The result is stimulation of bowel movements, shorter evacuation times, and easier stools.
Sodium picosulfate, as a laxative, affects only the large intestine, stimulating the natural removal of contents from the lower parts of the gastrointestinal tract. Therefore, sodium picosulfate does not affect the digestion or absorption of caloric foods and important nutrients in the small intestine.
A randomized double-blind study in parallel groups of 367 patients with chronic constipation examined the effects of guttalax®. The results of the study showed a significant increase in intestinal peristalsis during the week with the use of the drug compared to placebo during the whole 4-week treatment (p<0.0001). Serum potassium levels remained unchanged at the end of the study (4.4mm) and in accordance with physiologic norms (3.6-5.3 mm).
Testimony Guttalax
- as a remedy for constipation, it is recommended to use the drug in the following situations:
- Constipation caused by atony and hypotonia of the colon, including cases related to the patient's age, the condition of the bed patient, after surgery, after childbirth and during
- lactation;
- Constipation caused by medication;
- to regulate stool in cases of hemorrhoids, proctitis and anal fissures to reduce fecal consistency;
- in diseases of the gallbladder and irritable bowel syndrome, with constipation predominant;
- Constipation caused by intestinal dysbacteriosis or dietary disorders.
Method of use, course and dosage Guttalax
Starting treatment with a small dose of a drug is recommended. By gradually increasing the dosage, regular results in the form of normalization of stool can be achieved. However, it is important to take into account that you should not exceed the maximum recommended daily dose of the drug.
Due to the lack of drug addiction, dosage can be individually adjusted according to the patient's needs. Reducing the dose as needed or using the drug as needed may help.
- Nosology Guttalax (ICD codes)
- K58
- Irritable bowel syndrome
- K59.0
- Constipation
- K59.8
- Other specified functional intestinal disorders
- K60
- Anal and rectal fissure and fistula
- K62.8
- Other specified diseases of anus and rectum (including proctitis)
- K63.8
- Other specified diseases of intestine
- K64
- Hemorrhoids and perianal venous thrombosis
- K82.8
- Other specified diseases of gallbladder and cystic duct (including dyskinesia)
- O99.6
- Digestive disorders complicating pregnancy, childbirth, and the puerperium
